| Journal of Medical Cases, ISSN 1923-4155 print, 1923-4163 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Med Cases and Elmer Press Inc |
| Journal website http://www.journalmc.org |
Case Report
Volume 11, Number 1, January 2020, pages 30-33
Gemcitabine-Related Acute Coronary Syndrome
Table
| Author | Reported event | Age, gender, malignancy (origin, stage) | Duration of therapy | Dose | Cardiac history | Interval time (after infusion) | Outcome | Association |
|---|---|---|---|---|---|---|---|---|
| F: female; CMP: cardiomyopathy; CAD: coronary artery disease; NSTEMI: non-ST-segment elevation myocardial infarction; VT: ventricular tachycardia; IV: stage IV cancer; NK: not known; M: male; AF: atrial fibrillation; IIA: stage IIA cancer; CABG: coronary artery bypass graft. | ||||||||
| Ozturk et al [4] | Coronary vasospasm | 59, F, uterus, IV | Second cycle | 900 mg/m2 | CAD | 30 min | Survived | Strong |
| Bdair et al [5] | NSTEMI/VT | 43, F, lung, IV | Fifth cycle | 1,000 mg/m2 | CMP, CAD | 3 days | Survived | Strong |
| Katircibasi et al [6] | Coronary vasospasm | 64, F, ovary, IV | Second cycle | NK | No | 30 min | Survived | Strong |
| Kalapura et al [7] | NSTEMI, AF | 54, M, pancreas, IV | Fifth cycle | 1,900 mg/m2 | No | 6 h | Survived; AF recurred | Strong |
| Present case 1 | NSTEMI | 68, M, lung, IV | Firstt cycle | 1,950 mg/m2 | No | 5 days | Survived | Strong |
| Present case 2 | NSTEMI/cardiogenic shock | 84, M, pancreas, IIA | Second cycle | 1,950 mg/m2 | CAD, CABG | 2 h | Survived | Strong |